EU Approval for Vertex's Kalydeco - Analyst Blog

By
A A A

Vertex Pharmaceuticals Inc. ( VRTX ) recently received European approval of Kalydeco for treating people suffering from cystic fibrosis (CF). The European Commission approved the drug to treat patients with CF, aged 6 years and above and who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vertex intends to launch Kalydeco in Europe shortly.

The European approval did not come as a surprise as in May this year, the European Committee for Medicinal Products for Human Use (CHMP) voted in favor of approving the drug. Kalydeco is the first medicine that targets the underlying cause of CF, which is a rare genetic disease, caused by defective or missing CFTR proteins. Approximately 1,100 people have this mutation in Europe.

Notably, Vertex conducted two global phase III studies, determining the efficiency of Kalydeco in treating patients with CF. These studies revealed that Kalydeco improves breathing and other symptoms of CF patients aged 6 years and above.

Patients on Kalydeco showed improvements in lung function, weight gain and certain quality of life measurements in comparison to those on placebo. Favorable results from these studies backed the CHMP's positive opinion.

Vertex has a collaboration agreement with Cystic Fibrosis Foundation Therapeutics, Inc. for Kalydeco. According to the agreement, Cystic Fibrosis is entitled to receive royalties on net sales of Kalydeco.

Kalydeco is already available in the US, where it was approved in January 2012 for treating patients suffering from CF, with at least one copy of the G551D mutation in the CFTR gene. Vertex recorded sales of $18.4 million for the drug in the first quarter of 2012.

Currently, Vertex has another product marketed in the EU: Incivo. Vertex has an agreement with Johnson & Johnson ( JNJ ) to commercialize Incivo outside the US.

Our Recommendation

Given the strong first-quarter sales of Kalydeco in the US along with the EU approval, we believe the drug can be a major growth driver in the future. We expect investor focus to remain on Kalydeco's performance in the US as well as its launch progress in the EU.

We currently have a Neutral recommendation on Vertex. The stock carries a Zacks #3 Rank (Hold rating) in the short run.


 
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
 
VERTEX PHARM (VRTX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: CF , CHMP , JNJ , VRTX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Russell’s One Good Reason
Russell’s One Good Reason           
Tammy’s One Good Reason
Tammy’s One Good Reason             
Lisa’s One Good Reason
Lisa’s One Good Reason              

Stocks

Referenced

Most Active by Volume

87,324,760
  • $7.31 ▲ 22.04%
79,329,227
  • $17.16 ▲ 0.76%
74,153,988
  • $8.87 ▼ 5.84%
49,177,672
  • $34.01 ▲ 4.39%
44,197,901
  • $101.40 ▲ 1.38%
43,197,735
  • $11.70 ▲ 3.36%
42,712,021
  • $74.99 ▲ 1.19%
42,423,171
  • $108 ▲ 0.95%
As of 10/31/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com